Details of the Drug

General Information of Drug (ID: DM9OZWQ)

Drug Name

Lovastatin

Synonyms

lovastatin; 75330-75-5; mevinolin; Mevacor; Lovalip; Monacolin K; Lovalord; Mevinacor; Altoprev; Nergadan; Artein; Altocor; 6alpha-Methylcompactin; MK-803; Hipovastin; Lovastatine; Lovasterol; Paschol; Lipivas; Closterol; Teroltrat; Tecnolip; Rovacor; Cholestra; Rodatin; Lozutin; Lipofren; Lestatin; Hipolip; Colevix; Sivlor; Taucor; Lipdip; Belvas; Mevlor; Lovastatine [French]; Lovastatinum [Latin]; Lovastatina [Spanish]; 6-alpha-Methylcompactin; Lovastatinum; Lovastatina; Lovastin; MSD 803; MK 803; 6 alpha-Methylcompactin; UNII-9LHU78OQFD; Altocor; Liposcler; Mevinolin; Rextat; Sivlor;Taucor; Monakolin K; MK803; Advicor (TN); Altocor (TN); Altoprev (TN); L-154803; Lovastatin & Primycin; ML-530B; Mevacor (TN); Mevinolin from Aspergillus sp; Statosan (TN); Lovastatin (USP/INN); Lovastatin [USAN:BAN:INN]; Lovastatin, (1 alpha(S*))-Isomer; Lovastatin, 1 alpha-Isomer (without R*/S* notation); 2beta,6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone; 6 Methylcompactin; 6-Methylcompactin; Aspirin/lisinopril/ lovastatin fixed-dose combination

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Approved	[1]
Hypercholesterolaemia	5C80.0	Approved	[2]
Hyperlipidemia	5C80.Z	Approved	[1]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[1]
Hypertriglyceridemia	5C80.1	Approved	[1]
Melanoma	2C30	Approved	[1]
X-linked chondrodysplasia punctata 2	N.A.	Approved	[1]
Cardiovascular disease	BA00-BE2Z	Phase 3	[3]
Smith-Lemli-Opitz syndrome	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Anticholesteremic Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

404.5

Logarithm of the Partition Coefficient (xlogp)

4.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 3.013 mcg/L []
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3.36 h []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Elimination: Following an oral dose of 14C-labeled lovastatin to man, 10% of the dose was excreted in urine and 83% in feces []
Half-life: The concentration or amount of drug in body reduced by one-half in 13.37 hours []
Metabolism: The drug is metabolized via serum paraoxonase [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 3.28759 micromolar/kg/day [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.0004 mg/mL [4]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Cell-mediated cytotoxicity	Not Available	IL2	OTGI4NSA	[7]
Hepatotoxicity	Not Available	GPT	OTOXOA0Q	[7]
-----------

Chemical Identifiers

Formula: C24H36O5
IUPAC Name: [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
Canonical SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C
InChI: InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1
InChIKey: PCZOHLXUXFIOCF-BXMDZJJMSA-N

Cross-matching ID

PubChem CID: 53232
ChEBI ID: CHEBI:40303
CAS Number: 75330-75-5
DrugBank ID: DB00227
TTD ID: D06WTZ
VARIDT ID: DR00410
INTEDE ID: DR0986
ACDINA ID: D00377

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
HMG-CoA reductase (HMGCR)	TTPADOQ	HMDH_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DT3D8F0	SO1B1_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[12]
Mephenytoin 4-hydroxylase (CYP2C19)	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[12]
UDP-glucuronosyltransferase 2B7 (UGT2B7)	DEB3CV1	UD2B7_HUMAN	Substrate	[12]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[12]
Serum paraoxonase/lactonase 3 (PON3)	DETXQZ1	PON3_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)	OTRT3F3U	HMDH_HUMAN	Gene/Protein Processing	[14]
72 kDa type IV collagenase (MMP2)	OT5NIWA2	MMP2_HUMAN	Gene/Protein Processing	[15]
A-kinase anchor protein 7 isoforms alpha and beta (AKAP7)	OT0L3PZ6	AKA7A_HUMAN	Drug Response	[16]
Actin, aortic smooth muscle (ACTA2)	OTEDLG8E	ACTA_HUMAN	Gene/Protein Processing	[17]
Alanine aminotransferase 1 (GPT)	OTOXOA0Q	ALAT1_HUMAN	Drug Response	[7]
Amyloid-beta precursor protein (APP)	OTKFD7R4	A4_HUMAN	Protein Interaction/Cellular Processes	[18]
Ankyrin-2 (ANK2)	OTWB4R1Y	ANK2_HUMAN	Drug Response	[16]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Protein Interaction/Cellular Processes	[19]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[20]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[20]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Arteriosclerosis

ICD Disease Classification

BD40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
HMG-CoA reductase (HMGCR)	DTT	HMGCR	1.01E-05	0.65	1.53
P-glycoprotein 1 (ABCB1)	DTP	P-GP	3.29E-14	-7.08E-01	-1.99E+00
Organic anion transporting polypeptide 1B1 (SLCO1B1)	DTP	OATP1B1	3.27E-01	-5.78E-02	-3.84E-01
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	2.00E-01	5.79E-02	3.00E-01
Serum paraoxonase/lactonase 3 (PON3)	DME	PON3	2.30E-02	-3.44E-01	-1.20E+00
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	1.47E-02	-1.13E-01	-1.13E+00
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	4.03E-02	-1.19E-01	-5.11E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	3.24E-05	-3.48E-01	-1.34E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Lovastatin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Bempedoic acid	DM1CI9R	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[21]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Lovastatin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[22]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Lovastatin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[23]
BMS-201038	DMQTAGO	Major	Decreased metabolism of Lovastatin caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[24]
-----------

Coadministration of a Drug Treating the Disease Different from Lovastatin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[25]
Thioguanine	DM7NKEV	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Thioguanine.	Acute myeloid leukaemia [2A60]	[26]
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Lovastatin caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[27]
Midostaurin	DMI6E0R	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Midostaurin.	Acute myeloid leukaemia [2A60]	[28]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[29]
Daunorubicin	DMQUSBT	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Daunorubicin.	Acute myeloid leukaemia [2A60]	[29]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Lovastatin caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[28]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Lovastatin due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[28]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Lovastatin due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[28]
Ranolazine	DM0C9IL	Major	Decreased metabolism of Lovastatin caused by Ranolazine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[28]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Lovastatin caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[30]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Lovastatin caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[31]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[32]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Lovastatin caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[33]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Lovastatin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[25]
Ciprofloxacin XR	DM2NLS9	Moderate	Decreased metabolism of Lovastatin caused by Ciprofloxacin XR mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Lovastatin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[34]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Lovastatin caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[33]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Lovastatin caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[35]
Ag-221	DMS0ZBI	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Ag-221.	BCR-ABL1-negative chronic myeloid leukaemia [2A41]	[25]
Erdafitinib	DMI782S	Moderate	Increased metabolism of Lovastatin caused by Erdafitinib mediated induction of CYP450 enzyme.	Bladder cancer [2C94]	[36]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Lovastatin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[37]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[38]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Lovastatin caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Tucatinib	DMBESUA	Major	Decreased metabolism of Lovastatin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[39]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Lovastatin caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[31]
Grepafloxacin	DMGLX0T	Moderate	Decreased metabolism of Lovastatin caused by Grepafloxacin mediated inhibition of CYP450 enzyme.	Bronchitis [CA20]	[31]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Lovastatin caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[40]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Lovastatin caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[31]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Lovastatin caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[25]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[41]
MK-8228	DMOB58Q	Major	Decreased clearance of Lovastatin due to the transporter inhibition by MK-8228.	Cytomegaloviral disease [1D82]	[42]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Lovastatin caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[31]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Lovastatin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[39]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Lovastatin caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[43]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Lovastatin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[44]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Cannabidiol.	Epileptic encephalopathy [8A62]	[28]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Lovastatin caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Clotrimazole	DMMFCIH	Moderate	Decreased metabolism of Lovastatin caused by Clotrimazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[28]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Lovastatin caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[28]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Lovastatin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[45]
Omeprazole	DM471KJ	Moderate	Increased plasma concentrations of Lovastatin and Omeprazole due to competitive inhibition of the same metabolic pathway.	Gastro-oesophageal reflux disease [DA22]	[46]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Lovastatin caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[31]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Lovastatin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[33]
Simeprevir	DMLUA9D	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Simeprevir.	Hepatitis virus infection [1E50-1E51]	[47]
Telaprevir	DMMRV29	Major	Decreased metabolism of Lovastatin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[33]
Rifampin	DMA8J1G	Major	Accelerated clearance of Lovastatin due to the transporter induction by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[46]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Lovastatin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[48]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[49]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Lovastatin caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Lovastatin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Fostemsavir	DM50ILT	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[52]
Nevirapine	DM6HX9B	Moderate	Increased metabolism of Lovastatin caused by Nevirapine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Lovastatin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[39]
Tipranavir	DM8HJX6	Major	Decreased metabolism of Lovastatin caused by Tipranavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Efavirenz	DMC0GSJ	Moderate	Increased metabolism of Lovastatin caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Saquinavir	DMG814N	Major	Decreased metabolism of Lovastatin caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Lovastatin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[54]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Lovastatin and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Lovastatin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Darunavir	DMN3GCH	Major	Decreased metabolism of Lovastatin caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Lovastatin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Ritonavir	DMU764S	Major	Decreased metabolism of Lovastatin caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[51]
Levamlodipine	DM92S6N	Moderate	Decreased metabolism of Lovastatin caused by Levamlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Diltiazem	DMAI7ZV	Major	Decreased clearance of Lovastatin due to the transporter inhibition by Diltiazem.	Hypertension [BA00-BA04]	[31]
Amlodipine	DMBDAZV	Moderate	Decreased metabolism of Lovastatin caused by Amlodipine mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[31]
Conivaptan	DM1V329	Major	Decreased metabolism of Lovastatin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[33]
Tolvaptan	DMIWFRL	Minor	Decreased metabolism of Lovastatin caused by Tolvaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[56]
Lesinurad	DMUR64T	Moderate	Increased metabolism of Lovastatin caused by Lesinurad mediated induction of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[57]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Lovastatin caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[31]
Suvorexant	DM0E6S3	Moderate	Decreased metabolism of Lovastatin caused by Suvorexant mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[31]
Methotrexate	DM2TEOL	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Methotrexate.	Leukaemia [2A60-2B33]	[28]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Lovastatin caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[31]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Lovastatin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[58]
Ceritinib	DMB920Z	Major	Decreased metabolism of Lovastatin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[39]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Lovastatin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[59]
Osimertinib	DMRJLAT	Moderate	Increased metabolism of Lovastatin caused by Osimertinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[28]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Lovastatin caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[31]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[60]
Idelalisib	DM602WT	Major	Decreased metabolism of Lovastatin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[39]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Lovastatin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[31]
Clofarabine	DMCVJ86	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Clofarabine.	Mature B-cell lymphoma [2A85]	[61]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[25]
LGX818	DMNQXV8	Moderate	Increased metabolism of Lovastatin caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[62]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Lovastatin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[25]
Danazol	DML8KTN	Major	Decreased metabolism of Lovastatin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[34]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Lovastatin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[63]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Lovastatin and Thalidomide.	Multiple myeloma [2A83]	[55]
Bexarotene	DMOBIKY	Moderate	Increased metabolism of Lovastatin caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[28]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Lovastatin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Lovastatin caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Lovastatin caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Lovastatin caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[31]
Modafinil	DMYILBE	Moderate	Increased metabolism of Lovastatin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[25]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Lovastatin caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[34]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Lovastatin caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[31]
Olaparib	DM8QB1D	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Olaparib.	Ovarian cancer [2C73]	[25]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Lovastatin caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[31]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Lovastatin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[64]
Esomeprazole	DM7BN0X	Moderate	Increased plasma concentrations of Lovastatin and Esomeprazole due to competitive inhibition of the same metabolic pathway.	Peptic ulcer [DA61]	[46]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Lovastatin caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[65]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Lovastatin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[66]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Lovastatin caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[67]
Darolutamide	DMV7YFT	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Darolutamide.	Prostate cancer [2C82]	[28]
Bicalutamide	DMZMSPF	Moderate	Decreased metabolism of Lovastatin caused by Bicalutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[31]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Lovastatin due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[28]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Lovastatin due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[28]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Lovastatin caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[68]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Lovastatin due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Lovastatin due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Lovastatin due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Golimumab	DMHZV7X	Moderate	Altered metabolism of Lovastatin due to Golimumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Lovastatin due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Lovastatin caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[31]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Lovastatin caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[28]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Lovastatin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[31]
Armodafinil	DMGB035	Moderate	Increased metabolism of Lovastatin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[25]
LEE011	DMMX75K	Moderate	Decreased metabolism of Lovastatin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[31]
Naltrexone	DMUL45H	Moderate	Increased risk of hepatotoxicity by the combination of Lovastatin and Naltrexone.	Substance abuse [6C40]	[69]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[70]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Lovastatin due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[71]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Lovastatin caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[28]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Lovastatin and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[72]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Lovastatin and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[72]
Amiodarone	DMUTEX3	Major	Decreased metabolism of Lovastatin caused by Amiodarone mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[73]
-----------


⏷ Show the Full List of 125 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Glyceryl monostearate	E00310	24699	Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Acetyltributyl citrate	E00127	6505	Plasticizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Poloxamer 188	E00645	Not Available	Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Lovastatin 20 mg tablet	20 mg	24 HR Extended Release Oral Tablet	Oral
Lovastatin 40 mg tablet	40 mg	24 HR Extended Release Oral Tablet	Oral
Lovastatin 60 mg tablet	60 mg	24 HR Extended Release Oral Tablet	Oral
Lovastatin 10 mg tablet	10 mg	Oral Tablet	Oral
Lovastatin 40 mg tablet	40 mg	Oral Tablet	Oral
Lovastatin 20 mg tablet	20 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Lovastatin FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2739).
3	Clinical pipeline report, company report or official report of CardioPharma Wilmington.
4	BDDCS applied to over 900 drugs
5	Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C: Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
9	A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8.
10	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11	Metabolic interactions with statins. Tidsskr Nor Laegeforen. 2001 Jan 20;121(2):189-93.
12	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
13	Paraoxonases-1, -2 and -3: what are their functions? Chem Biol Interact. 2016 Nov 25;259(Pt B):51-62.
14	Desmosterol can replace cholesterol in sustaining cell proliferation and regulating the SREBP pathway in a sterol-Delta24-reductase-deficient cell line. Biochem J. 2009 May 13;420(2):305-15.
15	Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras. Oncol Rep. 2009 May;21(5):1317-22. doi: 10.3892/or_00000357.
16	NCI60 cancer cell line panel data and RNAi analysis help identify EAF2 as a modulator of simvastatin and lovastatin response in HCT-116 cells. PLoS One. 2011 Apr 4;6(4):e18306. doi: 10.1371/journal.pone.0018306.
17	Inhibitory effects of clinical reagents having anti-oxidative activity on transforming growth factor-1-induced expression of -smooth muscle actin in human fetal lung fibroblasts. J Toxicol Sci. 2011;36(6):733-40. doi: 10.2131/jts.36.733.
18	Protection against the Neurotoxic Effects of -Amyloid Peptide on Cultured Neuronal Cells by Lovastatin Involves Elevated Expression of 7 Nicotinic Acetylcholine Receptors and Activating Phosphorylation of Protein Kinases. Am J Pathol. 2018 Apr;188(4):1081-1093. doi: 10.1016/j.ajpath.2017.11.020. Epub 2018 Jan 16.
19	Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
20	Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res. 1999 Aug;5(8):2223-9.
21	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
22	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
23	Canadian Pharmacists Association.
24	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
25	Cerner Multum, Inc. "Australian Product Information.".
26	Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
27	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Multum Information Services, Inc. Expert Review Panel.
30	Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7. [PMID: 17064205]
31	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
32	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
33	Ayanian JZ, Fuchs CS, Stone RM "Lovastatin and rhabdomyolysis." Ann Intern Med 109 (1988): 682-3. [PMID: 3421582]
34	Andreou ER, Ledger S "Potential drug interaction between simvastatin and danazol causing rhabdomyolysis." Can J Clin Pharmacol 10 (2003): 172-4. [PMID: 14712320]
35	Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
36	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
37	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
38	Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
39	Alderman CP "Possible interaction between nefazodone and pravastatin." Ann Pharmacother 33 (1999): 871. [PMID: 10466919]
40	He K, Woolf TF, Hollenberg PF "Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486)." J Pharmacol Exp Ther 288 (1999): 791-7. [PMID: 9918590]
41	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
42	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
43	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
44	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
45	Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20. [PMID: 17368833]
46	Bogman K, Peyer AK, Torok M, Kusters E, Drewe J "HMG-CoA reductase inhibitors and P-glycoprotein modulation." Br J Pharmacol 132 (2001): 1183-92. [PMID: 11250868]
47	Product Information. Olysio (simeprevir). Janssen Pharmaceuticals, Titusville, NJ.
48	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
49	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
50	Product Information. Rescriptor (delavirdine). Pharmacia and Upjohn, Kalamazoo, MI.
51	Barry M, Mulcahy F, Merry C, Gibbons S, Back D "Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection." Clin Pharmacokinet 36 (1999): 289-304. [PMID: 10320951]
52	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
53	Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. "Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study." J Acquir Immune Defic Syndr 39 (2005): 307-12. [PMID: 15980690]
54	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
55	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
56	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
57	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
58	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
59	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
60	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
61	Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
62	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
63	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
64	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
65	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
66	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
67	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
68	Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
69	Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
70	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
71	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
72	Barshes NR, Goodpastor SE, Goss JA "Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient." Transplantation 76 (2003): 1649-50. [PMID: 14702546]
73	Chouhan UM, Chakrabarti S, Millward LJ "Simvastatin interaction with clarithromycin and amiodarone causing myositis." Ann Pharmacother 39 (2005): 1760-1. [PMID: 16159992]